Horizon Pharma Earns RS Rating Upgrade

An image of a pen, a tablet and a calculator Credit: Shutterstock photo

Horizon Pharma ( HZNP ) saw a positive improvement to its Relative Strength ( RS ) Rating on Thursday, with an increase from 64 to 77.

[ibd-display-video id=2368044 width=50 float=left autostart=true] IBD's proprietary rating identifies market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the last 52 weeks stacks up against all the other stocks in our database.

Over 100 years of market history reveals that the market's biggest winners often have an 80 or higher RS Rating in the early stages of their moves. See if Horizon Pharma can continue to show renewed price strength and clear that threshold.

Looking For Winning Stocks? Try This Simple Routine

Now is not an ideal time to jump in since it isn't near a proper buy zone, but see if the stock goes on to form a base and break out.

Earnings growth fell in the most recent quarter from -27% to -63%. But sales moved higher, from 12% to 30%.

The company earns the No. 7 rank among its peers in the Medical-Ethical Drugs industry group. AbbVie ( ABBV ), Zoetis ( ZTS ) and Novo Nordisk ( NVO ) are among the top 5 highly rated stocks within the group.

RELATED:

Biotech And Pharmaceutical Industry And Stock News

Stocks With Rising Relative Strength Ratings

Why Should You Use IBD's Relative Strength Rating?

How Relative Strength Line Can Help You Judge A Stock

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.